Skip to main content
. 2021 Jan 15;7:609322. doi: 10.3389/fmolb.2020.609322

Figure 1.

Figure 1

Flowchart shows patient selection. HCC, hepatocellular; BCLC, Barcelona Clinic Liver Cancer; ECOG-PS, Eastern Cooperative Oncology Group performance status; TACE, transarterial chemoembolization; Sor, sorafenib; ICIs, immune checkpoint inhibitors.